SGLT2 inhibitors have established application in the treatment of type 2 diabetes in COPD (NICE, 2013) and potential application as an insulin adjunct in the treatment of the insulin‐deficient diabetes seen in CF (Argento and Nakamura, 2016). The gene discussed is SLC5A2; the disease is cystic fibrosis.